Determination of ITPA gene variants is a good predictive strategy of ribavirin-induced anemia, thus genotyping before starting antiviral treatment can work as a biomarker and play a prognostic role in clinical practice for pretreatment screening, therapy individualization, improving treatment outcome and reduction of ribavirin-associated Hb decline [15]. Here, GSTM1 is linked to anemia.